SG10201800309SA - Adrenomedullin to guide therapy of blood pressure decline - Google Patents
Adrenomedullin to guide therapy of blood pressure declineInfo
- Publication number
- SG10201800309SA SG10201800309SA SG10201800309SA SG10201800309SA SG10201800309SA SG 10201800309S A SG10201800309S A SG 10201800309SA SG 10201800309S A SG10201800309S A SG 10201800309SA SG 10201800309S A SG10201800309S A SG 10201800309SA SG 10201800309S A SG10201800309S A SG 10201800309SA
- Authority
- SG
- Singapore
- Prior art keywords
- adrenomedullin
- blood pressure
- pressure decline
- guide therapy
- therapy
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13160265 | 2013-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201800309SA true SG10201800309SA (en) | 2018-02-27 |
Family
ID=47901848
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507774YA SG11201507774YA (en) | 2013-03-20 | 2014-03-19 | Adrenomedullin to guide therapy of blood pressure decline |
| SG10201800309SA SG10201800309SA (en) | 2013-03-20 | 2014-03-19 | Adrenomedullin to guide therapy of blood pressure decline |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507774YA SG11201507774YA (en) | 2013-03-20 | 2014-03-19 | Adrenomedullin to guide therapy of blood pressure decline |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10598674B2 (de) |
| EP (1) | EP2976646B1 (de) |
| JP (3) | JP6259905B2 (de) |
| CN (2) | CN108362885B (de) |
| CA (1) | CA2907467A1 (de) |
| DK (1) | DK2976646T3 (de) |
| ES (1) | ES2830036T3 (de) |
| HK (2) | HK1216264A1 (de) |
| RU (1) | RU2673455C2 (de) |
| SG (2) | SG11201507774YA (de) |
| WO (1) | WO2014147153A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018010269A2 (pt) * | 2015-11-27 | 2019-02-05 | Brahms Gmbh | mr-proadm como marcador para o status do volume extracelular de um indivíduo |
| CN109716136B (zh) * | 2016-07-08 | 2023-09-22 | 斯弗因高泰克有限公司 | 肾上腺髓质素用于评估急性心力衰竭患者的充血 |
| EP3309550A1 (de) * | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Verfahren zum nachweis von apolipoprotein e4 |
| JP6855118B2 (ja) * | 2017-03-14 | 2021-04-07 | 東ソー株式会社 | 全身状態の良不良を評価するための情報を提供する方法及び測定試薬 |
| WO2018181638A1 (ja) * | 2017-03-29 | 2018-10-04 | 国立大学法人宮崎大学 | 長時間作用型アドレノメデュリン誘導体 |
| CN107194129B (zh) * | 2017-06-30 | 2019-08-06 | 江南大学 | 一种应用乳酸修正的adm1模型分析餐厨垃圾产甲烷的方法 |
| EP3438668A1 (de) | 2017-08-04 | 2019-02-06 | B.R.A.H.M.S GmbH | Diagnose und risikostratifizierung von pilzinfektionen |
| JP7258860B2 (ja) * | 2017-09-13 | 2023-04-17 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ |
| WO2019053115A1 (en) * | 2017-09-13 | 2019-03-21 | B.R.A.H.M.S Gmbh | USE OF PROADM AS A THERAPEUTIC SURVEILLANCE MARKER FOR CRITICALLY PHASE PATIENTS |
| JP7291688B2 (ja) * | 2017-09-13 | 2023-06-15 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 重篤患者における腎置換療法のための指標としてのアドレノメズリン前駆体 |
| PL3682247T3 (pl) | 2017-09-13 | 2022-04-25 | B.R.A.H.M.S Gmbh | Proadrenomedulina jako marker nieprawidłowych poziomów płytek krwi |
| EP4159230A1 (de) * | 2017-09-25 | 2023-04-05 | AdrenoMed AG | Anti-adrenomedullin (adm)-bindemittel zur verwendung in der therapie oder vorbeugung von krankheitssymptomen |
| CN111480076A (zh) * | 2017-10-18 | 2020-07-31 | 艾德里诺医药公司 | 抗肾上腺髓质素（adm）结合剂治疗下的疗法监测 |
| EP3502706A1 (de) * | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow für risikobewertung und patientenmanagement unter verwendung von procalcitonin und midregional-proadrenomedullin |
| EP3729083A1 (de) * | 2017-12-20 | 2020-10-28 | B.R.A.H.M.S GmbH | Antibiotikatherapieanleitung auf basis von pro-adm |
| EP3578989A1 (de) * | 2018-06-06 | 2019-12-11 | B.R.A.H.M.S GmbH | Pro-adm zur prognose von traumabedingten komplikationen bei polytraumapatienten |
| CA3119792A1 (en) * | 2018-11-15 | 2020-05-22 | Ferring B.V. | Compounds, compositions and methods for treating sepsis |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8519425D0 (en) | 1985-08-01 | 1985-09-04 | Ici Plc | Amine production |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2774769B2 (ja) * | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| AU2002323501C1 (en) | 2001-08-30 | 2010-04-29 | Biorexis Technology, Inc | Modified transferrin fusion proteins |
| DK1531791T3 (da) | 2002-06-07 | 2010-11-01 | Dyax Corp | Forebyggelse og begrænsning af iskæmi |
| DE10316583A1 (de) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| US20050148029A1 (en) * | 2003-09-29 | 2005-07-07 | Biosite, Inc. | Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| WO2006032436A2 (en) | 2004-09-21 | 2006-03-30 | Nascacell Technologies Ag. | Use of microproteins as tryptase inhibitors |
| WO2007041623A2 (en) * | 2005-10-03 | 2007-04-12 | Biosite Incorporated | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
| US8906857B2 (en) * | 2005-12-01 | 2014-12-09 | B.R.A.H.M.S. Gmbh | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
| DE102006060112A1 (de) * | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
| WO2009009907A1 (en) * | 2007-07-18 | 2009-01-22 | The University Of British Columbia | Use of vasopressin-receptor agonists for the treatment of septic shock |
| EP2231860B1 (de) | 2007-12-19 | 2011-10-05 | Affibody AB | Pdgf-bindendes polypeptid aus protein a |
| US20090304673A1 (en) * | 2008-06-10 | 2009-12-10 | Bernd Buchberger | Method of Treatment of Inflammatory Diseases |
| WO2010060748A1 (en) | 2008-11-03 | 2010-06-03 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
| CA2772162C (en) | 2009-08-27 | 2018-05-22 | Covagen Ag | Anti-il-17a fynomers and medical uses thereof |
| US20120301393A1 (en) | 2009-12-14 | 2012-11-29 | Scil Proteins Gmbh | Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin |
| CN105949301B (zh) | 2010-06-08 | 2020-03-27 | 皮里斯制药有限公司 | 结合IL-4受体α的泪脂质运载蛋白突变蛋白 |
| BR112012032406A2 (pt) * | 2010-06-18 | 2016-10-25 | Cezanne S A S | marcadores para o prognóstico e avaliação de risco de hipertensão induzida pela gravidez e pré-eclâmpsia |
-
2014
- 2014-03-19 RU RU2015144699A patent/RU2673455C2/ru active
- 2014-03-19 DK DK14711741.0T patent/DK2976646T3/da active
- 2014-03-19 ES ES14711741T patent/ES2830036T3/es active Active
- 2014-03-19 SG SG11201507774YA patent/SG11201507774YA/en unknown
- 2014-03-19 US US14/778,114 patent/US10598674B2/en active Active
- 2014-03-19 CA CA2907467A patent/CA2907467A1/en active Pending
- 2014-03-19 JP JP2016504582A patent/JP6259905B2/ja active Active
- 2014-03-19 WO PCT/EP2014/055554 patent/WO2014147153A1/en active Application Filing
- 2014-03-19 CN CN201810035720.XA patent/CN108362885B/zh active Active
- 2014-03-19 CN CN201480010451.1A patent/CN105102985B/zh active Active
- 2014-03-19 SG SG10201800309SA patent/SG10201800309SA/en unknown
- 2014-03-19 EP EP14711741.0A patent/EP2976646B1/de active Active
-
2016
- 2016-04-13 HK HK16104224.2A patent/HK1216264A1/zh unknown
-
2017
- 2017-12-11 JP JP2017236881A patent/JP2018059947A/ja not_active Ceased
-
2019
- 2019-01-17 HK HK19100872.2A patent/HK1258520A1/zh unknown
- 2019-12-25 JP JP2019234773A patent/JP6820399B2/ja active Active
-
2020
- 2020-02-04 US US16/781,226 patent/US20200249246A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015144699A (ru) | 2017-04-28 |
| CN108362885B (zh) | 2021-05-14 |
| HK1216264A1 (zh) | 2016-10-28 |
| ES2830036T3 (es) | 2021-06-02 |
| DK2976646T3 (da) | 2020-11-16 |
| CN108362885A (zh) | 2018-08-03 |
| EP2976646A1 (de) | 2016-01-27 |
| JP6820399B2 (ja) | 2021-01-27 |
| CA2907467A1 (en) | 2014-09-25 |
| EP2976646B1 (de) | 2020-08-19 |
| JP6259905B2 (ja) | 2018-01-10 |
| CN105102985B (zh) | 2018-05-18 |
| JP2016521351A (ja) | 2016-07-21 |
| CN105102985A (zh) | 2015-11-25 |
| JP2018059947A (ja) | 2018-04-12 |
| US20170010286A1 (en) | 2017-01-12 |
| US20200249246A1 (en) | 2020-08-06 |
| RU2673455C2 (ru) | 2018-11-27 |
| SG11201507774YA (en) | 2015-10-29 |
| JP2020073896A (ja) | 2020-05-14 |
| WO2014147153A1 (en) | 2014-09-25 |
| HK1258520A1 (zh) | 2019-11-15 |
| US10598674B2 (en) | 2020-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1258520A1 (zh) | 用於指導血壓下降療法的腎上腺髓質素 | |
| IL287516A (en) | Medicinal uses of empagliflozin | |
| HRP20190101T1 (hr) | Terapeutske uporabe empagliflozina | |
| HK1213818A1 (zh) | 依帕列淨的治療用途 | |
| HK1221424A1 (zh) | 治療癌症的藥物組合 | |
| EP2968732A4 (de) | Flüssigkeitsabgabesystem und verfahren zur flüssigkeitsverabreichung an einen patienten | |
| FI3626270T3 (fi) | Sydän- ja verisuonitautien hoito | |
| LT2981271T (lt) | Empagliflozino terapinis panaudojimas | |
| EP2977014A4 (de) | Katheter zur behandlung von sinusitis | |
| EP2958964A4 (de) | Behandlung von häufig berührten oberflächen zur hygieneverbesserung | |
| ZA202207530B (en) | Use of phenoxypropylamine compounds to treat depression | |
| GB201607581D0 (en) | Treatment of cancer | |
| EP3019872A4 (de) | Neuartig verfahren zum targeting von glykoproteinen zur behandlung von krebs | |
| HK1232118A1 (zh) | 癌症的治療 | |
| EP2996716A4 (de) | Wirksamkeitskorrelate bezüglich krebsimpfstoffe | |
| GB201322347D0 (en) | Treatment of cancer | |
| GB201318742D0 (en) | Treatment of cancer | |
| GB201308529D0 (en) | Treatment of cancer | |
| GB201305020D0 (en) | Treatment of cancer | |
| GB201200262D0 (en) | Therapy of breast cancer |